Turner Parkinson Advise on Sale of Manchester Biotech Company

Turner Parkinson’s Corporate team, working alongside Baker Tilly, has advised the shareholders of Manchester-based biotech company Euprotec Ltd on the sale of the business to German company Evotec AG.

Euprotec, based in the Manchester Science Park on Lloyd Street North, is a specialist contract research organisation, providing infectious disease and respiratory biology services. The company, which was founded in 2008, supports each stage of anti-infective drug discovery and development programmes through to late stage pre-clinical investigation and clinical proof-of-concept studies. 

Hamburg-based Evotec is a fully integrated drug discovery and early development partner for Pharma and biotechnology companies. 

James Sheridan, Head of Corporate, led the Turner Parkinson team alongside team, working alongside James were David Easdown and Robin Hastings. James said “having worked on a number of CRO and pharma projects over the last 2 or 3 years, we were well placed to advise on this deal.  Euprotec is a great business which Peter and Lloyd have built from the ground up. We continue to show strength in working with growing businesses in the region to build and maximise value and are committed to further developing our life sciences, pharma and healthcare offering.  The TP team continues to drive forward with an impressive deal volume for the calendar year.”

Dr Werner Lanthaler, Chief Executive Officer of Evotec AG said “through the acquisition of Euprotec’s capabilities and its disease biology know-how in infection, Evotec is expanding its technological portfolio to offer a complete infrastructure and discovery solutions in the field of infectious diseases.”

Dr Lloyd Payne, CEO of Euprotec, added “we are thrilled to be joining forces with Evotec and combining its leading-edge drug discovery platform with Euprotec’s comprehensive infectious disease biology capabilities and expertise. Our vision of delivering integrated, world-class anti-infective discovery solutions to our clients will now be realised. We look forward to an exciting new phase of growth with Evotec and, most importantly, working with our customers to accelerate the development of new breakthrough anti-infective vaccines and therapies.” 

James Wild, Baker Tilly Corporate Finance Director said “we have worked with Euprotec for a number of years, and we were delighted to be able to advise the shareholders on this deal. This deal strengthens our position as a leading advisor to fast growing companies in the North West.”